News for Targovax ASA (TA5.MU)

Published at

Mar 4, 2021 4:47 PM

by markets.businessinsider.com

positive

positive

Targovax ASA: Registration of share capital increase following exercise of options

OSLO, Norway, March 4, 2021 /PRNewswire/ -- Oslo, 4 March 2021: Reference is made to the stock exchange announcement by Targovax ASA (OSE: TRVX) (...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 23, 2021 7:16 AM

by markets.businessinsider.com

positive

positive

Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up

OSLO, Norway, Feb. 23, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to tar...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 18, 2021 7:43 AM

by markets.businessinsider.com

positive

positive

Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021

OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat so...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 18, 2021 7:39 AM

by prnewswire.com

positive

positive

Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021

/PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 18, 2021 7:39 AM

by markets.businessinsider.com

positive

positive

Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021

OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat so...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 15, 2021 7:15 AM

by prnewswire.com

positive

positive

Targovax receives Fast-Track designation for ONCOS-102

/PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 10, 2021 7:22 AM

by markets.businessinsider.com

positive

positive

Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

- The parties will explore the feasibility and effect of combining their respective oncolytic virus and receptor tyrosine kinase (RTK) inhibitor t...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 10, 2021 7:18 AM

by markets.businessinsider.com

positive

positive

Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

OSLO, Norway, Feb. 10, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to tar...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 10, 2021 7:18 AM

by thestreet.com

positive

positive

Targovax And Papyrus Therapeutics Enter Research Collaboration To Develop Novel ONCOS Viruses With Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

OSLO, Norway, Feb. 10, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →
Published at

Feb 10, 2021 7:18 AM

by prnewswire.com

positive

positive

Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

/PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today...

TRVXO.OL TRVX.OL TA5.SG TA5.MU TA5.F

Read more →